Loading…
Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.
Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.
Sells its toxin and fillers to clinics, relying on distributors in each export market and on regulatory approvals country by country. Its toxin, also sold as Letybo, won US FDA approval in 2024, opening the largest aesthetics market. Exports are a large part of sales.
In one line: Korea's Allergan/Botox equivalent.
Moat: narrow (regulatory licence, brand). Regulatory-approved toxin strains and manufacturing scale are hard and costly to replicate.
Headquarters: Chuncheon, South Korea · Founded: 2001 · Employees: 629
Size Hugel (145020.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.52B, the 167th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩187,500 on 6 Nov 2026.
Performance Over six months the shares fell 25.7%, against -19.4% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +24.8%); the operating margin is 38.1% (peer median -297.1%).
Valuation It trades at 15.7× forward earnings against a peer median of 25.7× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.0 points above its cost of capital (5.4% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩471B | ₩425B | ₩373B | ₩320B | ₩282B |
| Revenue growth | — | +14% | +17% | +13% | — |
| Gross profit | n/a | ₩323B | ₩278B | ₩238B | ₩211B |
| EBITDA | n/a | ₩220B | ₩181B | ₩132B | ₩115B |
| Net income | ₩126B | ₩141B | ₩136B | ₩93.1B | ₩60.7B |
| Free cash flow | n/a | ₩137B | ₩137B | ₩94.0B | ₩47.8B |
| Capital expenditure | n/a | ₩29.5B | ₩33.3B | ₩40.6B | ₩45.0B |
| Total debt | n/a | ₩29.1B | ₩37.6B | ₩90.5B | ₩101B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hugel 145020.KS | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% |
| Medy-Tox 086900.KS | $310M | -39% | +7% | 7% | 19.9× | 6.0% |
| Daewoong Pharm 069620.KS | $874M | -30% | +9% | 12% | 5.8× | n/a |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 18.4× | -0.1% |
| Ipsen IPN.PA | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 145020.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.1% | -6.8% | 6th highest of 21 |
| 6-month return | -25.7% | -19.4% | 7th lowest of 18 |
| Distance from 52-week high | -39.2% | -43.6% | 9th highest of 21 |
| Revenue growth (TTM) | +16.6% | +24.8% | 7th lowest of 18 |
| Operating margin | 38.1% | -297.1% | 2nd highest of 18 |
| Forward P/E | 15.7× | 25.7× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -7.9% | -1.2% | least demanding of 4 |
| Growth delivered (Del g) | +15.0% | +25.6% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | -23.0 pp | -26.8 pp | 2nd most demanding of 4 |
| ROIC minus cost of capital | +8.0 pp | -34.0 pp | 2nd highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% | +15.0% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | 48.2× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 7.6× | -4.1% | +33.5% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 51.3× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | n/a | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 8.6× | -1.2% | +25.6% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | n/a | n/a | n/a |